2nd Annual Gene and Cell Therapy: Quality Developments to Commercialization Summit
26-27

October 2020

Germany

Munich

Munich Marriott Hotel

Berliner Str. 93, 80805

About

We are pleased to invite you to the 2nd Annual Gene and Cell Therapy: Quality Developments to Commercialization Summit. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The Summit will shed light on the delivery of cost and quality efficient process development, manufacturing and commercialisation of cell and gene therapies. It is an honour and privilege to invite you to partic...

We are pleased to invite you to the 2nd Annual Gene and Cell Therapy: Quality Developments to Commercialization Summit. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The Summit will shed light on the delivery of cost and quality efficient process development, manufacturing and commercialisation of cell and gene therapies. It is an honour and privilege to invite you to participate in this Summit.

more info
Who Should Attend

Chief Executives, Vice Presidents, Directors, Heads, Leaders and Managers specialising in:

  • Advanced Therapy Production
  • Analytical
  • Biotherapeutics
  • Cell Engineering
  • Cellular Immunotherapy
  • Clinical Development
  • Gene Therapy
  • GTMPs (Gene Therapy Medicinal Products)
  • Health Economics
  • Immuno-Oncology
  • Immunology Chemistry
  • Legal/IP
  • Market Access
  • Oncology
  • Pricing
  • Quality Control
  • Regenerative Medicine
  • Safety
  • Stem Cell
  • Tissue Therapy
  • ATMP (Advanced Therapy Medicinal Product)
  • Bioprocessing
  • CAR-T
  • Cell Therapy
  • Cellular Therapy
  • CMC
  • GMP
  • CBMPs (Cell-Based Medicinal Products)
  • Immune Deficiencies
  • Immunology
  • Immunotherapy
  • Manufacturing
  • Medical
  • Precision Medicine
  • Process Development
  • R&D
  • Regulatory
  • Sales
  • Supply Chain
Key Practical Learning Points of the Summit

Optimised cell and gene therapies process development, manufacturing, cost and quality efficiency towards successful commercialisation
Emerging science and technologies to enhance cell and gene therapies development
Advanced analytical approaches to improve quality control and real-time release
CMC technical and regulatory compliance to empower cell and gene therapy products development roadmap
Robust supply chain design for precision medicine therapies
Speakers
Dr. Rajesh Thangapazham, US

Head of Regulatory Strategy & Innovation, Cell & Gene Technologies

Lonza Pharma Biotech & Nutrition

Dr. Tam Soden, US

Sr. Director & Head of Analytical Development, Process Development Cell

Kite, a Gilead Company

Dr. James Wang, US

Global Quality Auditor, Cell & Gene Therapy

Novartis

Alex Klarer, US

Senior Engineer

Hitachi Chemical Advanced Therapeutic Solutions

Chaminda Salgado, UK

Scientific Leader Cell & Gene Therapy Platform CMC Platform Technology & Sciences

GSK

Dr. Peter de Haan, NL

CSO & Co-Founder

CSO & Co-Founder

Sarah Thomas, US

Vice President of Quality

REGENXBIO

Dr. Wenliang Dong, NL

Chief Operational Officer

ORCA Therapeutics BV

Dr. Christiane Niederlaender, UK

Director

AMBR Consulting Ltd

Bernadette Keane, US

Owner & Former VP Quality at bluebird bio

Keane Consulting LLC

Dr. Simon Briggs, CH

Sr. Technical Product Steward, Cell & Gene Therapy

Novartis

Dr. Jef Pinxteren, BE

Owner & Former Director of Process Development / VP Operations at Promethera Biosciences

Cell Applied Research

Alfred Luitjens, NL

Global Technical Director

Batavia Biosciences

Dr. Cosmin Pocanschi, DE

Business Development Manager

CeGaT GmbH

Annual

Events

Sponsors and Partners

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Media partner

"